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A RANDOMIZED CONTROLLED PILOT STUDY COMPARING AQUEOUS CREAM 
WITH A BEESWAX AND HERBAL OIL CREAM IN THE PROVISION OF RELIEF 
FROM POST-BURN PRURITIS 
 
 
ABSTRACT  
Post-burn itch is reported to affect up to 87% of the burn population. While 
treatments for post-burn itch are multimodal, they remain consistently ineffective. 
However, recent anecdotal evidence from several outpatients at a tertiary referral 
hospital suggests a cream combining bees wax and several herbal oils may be 
effective in the minimization of post-burn itch. The aim of this study was to test the 
efficacy of the bees wax and herbal oil cream against the standard treatment of 
aqueous cream in the provision of relief from the symptoms of post-burn itch. A 
randomized controlled trial compared two groups using a visual analogue scale, 
frequency of cream application, itch recurrence post cream application, use of 
antipruritic medications, and sleep disturbance to determine the effect of itch severity 
and duration. Fifty-two participants were enrolled in the study (84% male) with a 
mean age of 35 years (SD 16) and presenting mean burn total body surface area of 
7.2% (SD 7.7). Study results found the beeswax and herbal oil cream to reduce itch 
post application more frequently than aqueous cream (p=0.001). Additionally, when 
managed with beeswax and herbal oil cream, participants found their itch recurred 
later (p0.001) and their use of antipruritic medications was lower (p=0.023). 
Findings of this study suggest beeswax and herbal oil cream to be more effective in 
the minimization of post-burn itch than aqueous cream. Given this, a larger study 
examining the efficacy of beeswax and herbal oil cream appears warranted. 
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INTRODUCTION 
Between the years 2000 and 2004 approximately 46,611 people were hospitalized in 
Australia as a result of burn or scald related injury.1 Whilst burn comorbidities such 
as infection and psychosocial health alterations are readily described, it is also 
recognised that patients recovering from burn injury frequently experience a post-
burn itch.2-5 Itch has been described as a sensation inducing the urge to scratch.6  
Post-burn itch varies in time frame as well as severity and is reported to affect up to 
87% of the burn population.7 Frequently patients experience itch so severe and 
debilitating it disturbs their sleep, activities of daily living and their quality of life for 
months and sometimes years following wound healing.3 As a result of patient 
scratching, post-burn itch has also been associated with wound breakdown and 
infection as the interruption of fragile healing skin allows microorganisms to colonise 
and infect an area.3 This may result in increased length of hospital stay and 
additional outpatient visits, further escalating healthcare costs in this population. 
 
The visual analogue scale has been described as the ‘gold standard’ for measuring 
itch.7 Numerous studies have validated use of the visual analogue scale in the 
measurement of post-burn itch, demonstrating the participants ability to indicate the 
level of itch they experience prior to and/or post application of treatment modalities.6-
10 Past trials addressing post-burn itch have examined bath products3, antihistamine 
use, 9-11 local anaesthetic,12,13 massage,5,7,14 transcutaneous electrical nerve 
stimulation (TENS),15,16 varied oral medications,4,17-19 and dressings.20-22 Despite this 
multimodality, post-burn itch treatments remain consistently ineffective and further 
study is required in this area.4,7-11,23,24   
Research into reduction of post-burn itch has focused on the use of antihistamines; 
whether they are successful, whether their sedating side effect is the reason they are 
perceived as effective, and whether the effect on patient’s activities of daily living 
makes this treatment modality worthwhile to the individual.9-11 Interestingly, whilst 
many studies note use of a moisturising cream as standard for healing burns, the 
moisturising effect related to the relief of itch has not been formally examined. 
Further, literature yields no research centred around comparing the effectiveness of 
different moisturising creams in the management of post-burn itch. It would appear 
that although use of a moisturiser is seen as a component in helping patients to 
reduce their itch, it is not seen as a major focus for itch reduction. One study, which 
compared antihistamine cream to moisturising cream focused on the replacement of 
combined therapy (oral antihistamine and moisturising cream) with antihistamine 
cream alone.13 It was suggested that the antihistamine cream may provide improved 
relief from post-burn itch.  
 
Historic healing remedies such as honey, beeswax and propolis (a resinous mixture 
that honey bees collect from tree buds, sap flows, or other botanical sources) still 
maintain popularity today.25 Purported to possess anti-inflammatory and 
immunodilatory activities, numerous studies have found beeswax to successfully 
assist in wound healing.26-28 Beeswax has also been used in burn wound 
management and is found in MEBO (Moist Exposed Burn Ointment) (Julphar, Gulf 
Pharmaceutical Industries, UAE).29 Recent anecdotal evidence from several Royal 
Brisbane and Women’s Hospital (RBWH) burn outpatients, suggests Medilixir® – a 
beeswax and herbal oil cream – to successfully assist in the minimization of post-
burn itch. This small patient cohort applied Medilixir® (manufactured by Medilixir Pty 
Ltd in Brisbane, Australia) in preference to aqueous cream on their regenerated 
post-burn skin.  
 
Despite multiple attempts to resolve or reduce post-burn itch, no study has identified 
any treatment as successful in isolation.3,8-10 It would appear treatment of post-burn 
itch should be multifocal, polypharmologic, and designed on an individual basis with 
a multidisciplinary approach.19,23,24 Given the problems surrounding the management 
of post-burn itch, investigation of Medilixir® as a post-burn anti-pruritic appears 
warranted. The aim of this study was to test the efficacy of Medilixir® against the 
standard treatment of aqueous cream in the provision of relief from the symptoms of 
post-burn itch. 
 
METHODS 
Study patients and setting 
The Royal Brisbane and Women’s Hospital (RBWH) is a 986-bed metropolitan, 
government funded, public, tertiary referral teaching hospital. It has a number of 
specialties including burns with the RBWH Professor Stuart Pegg Adult Burns Centre 
admitting approximately 400 patients annually. In line with literature, the Professor 
Stuart Pegg Adult Burns Centre utilises various combinations of antihistamine 
medications, antipruritic  medications, regular bathing, massage and the application 
of aqueous cream to newly healed skin in their management of post-burn itch. 
Despite these varied interventions and their multiple combinations, itch remains a 
problem at the Professor Stuart Pegg Adult Burns Centre, as it does globally.  
 
This study was conducted between March and August 2008. All patients admitted to 
the Professor Stuart Pegg Adult Burns Centre between 10th of March and 22nd of 
July 2008 who met inclusion criteria were approached for study entry. Inclusion 
criteria were: direct admission to the burns unit (admissions from intensive care and 
high dependency were excluded); 18-80 years of age; capacity to provide informed 
consent; no allergy to Medilixir®. Ethical approval for this study was granted by the 
RBWH Human Research Ethics Committee. 
 
Procedure and assessments 
To compare whether or not Medilixir® is more effective than aqueous cream in 
reducing the severity and/or duration of post-burn itch this study used a prospective, 
randomized controlled trial to compare two groups. Moisturizing cream used by the 
control group was aqueous cream; moisturizing cream used by the treatment group 
was Medilixir®. The aqueous cream used by the RBWH Professor Stuart Pegg Adult 
Burns Centre is manufactured by Biotech Pharmaceuticals Pty Ltd and contains 
paraffin – white soft, emulsifying wax, glycerol, paraffin – heavy liquid, 
phenoxyethanol, water – purified. Medilixir® (manufactured by Medilixir Pty Ltd) 
contains cocos nucifera (coconut) oil, elaeis guineensis (palm) oil, ricinus communis 
(castor) oil, olea europaea (olive) fruit oil, cera alba (beeswax), eupatorium 
cannabinum (hemp) seed oil, triticum vulgare (wheat) germ oil, brassica napus 
(canola) seed oil. 
 
For the purpose of this research, itch/pruritis was defined as the sensation of itch 
and the urge to scratch the skin. The visual analogue scale has been described as 
the “Gold Standard” for pruritis measurement7 and has been used in multiple papers 
to measure post-burn itch.3,5,12,13 As well as using the visual analogue scale, this 
study collected the following data to further measure itch: sleep disturbance; use of 
antipruritic medications; and frequency of cream applications per day. 
 
All admissions to the Professor Stuart Pegg Adult Burns Centre who consented to 
study participation were patch tested with Medilixir® to identify any potential allergic 
response. A three square centimeter application of Medilixir® was applied to intact 
skin distal to the burn site; this was monitored for 48 hours for any sign of allergy. 
Following a response free patch test, patients were enrolled in the study and 
randomly assigned to either the control group (aqueous cream) or the treatment 
group (Medilixir®). Data collection commenced upon day 1 of cream application and 
continued for a 14 day period. Consistent with the management of all Professor 
Stuart Pegg Adult Burns Centre patients, moisturizing cream is only applied to 
regenerated, intact skin. As such, the initial application of moisturizing cream always 
occurred ‘some’ days following the burn injury. Study data were collected daily for a 
14 day period starting on day one of moisturizing cream application. 
 
Calculations were performed using version 15.2 of the Statistical Package for the 
Social Sciences (SPSS). The descriptive properties of demographic data and burn 
characteristics are given as frequencies (%), means and standard deviations as 
indicated. Pearson chi-square and Mann-Whitney U tests were used for the 
comparison between the control and the treatment groups. Pearson chi-square was 
used to evaluate itch reduction, itch recurrence, antipruritic medication use and sleep 
disturbance (all binary variables with the exception of itch recurrence which was 
categorical). Number of daily cream applications were evaluated by Mann-Whitney U 
test (as the variable was skewed to the right and not normally distributed). No power 
analyses were conducted. This study was a pilot trial and funding restricted the 
number of patients who could be recruited. Additionally, a magnitude of effect could 
not be determined as Medilixer’s® ability to reduce itch was unknown prior to the 
commencement of this trial. For all tests, the significance criterion was a probability 
of less than 0.05. 
 
RESULTS 
During the study period 78 patients meeting inclusion criteria were admitted to the 
Professor Stuart Pegg Adult Burns Centre. Of the 78 patients, 52 were recruited for 
this study; 22 patients declined study participation while four (7.1%) consented but 
were excluded following a Medilixir® patch test reaction. Medilixir® reaction in all four 
instances presented as localized mild erythema only (one of the four participants 
also complained of mild itch at the patch test site). In no instance were systemic or 
widespread changes noted and on all four occasions the erythema subsided within 
48 hours. Patient demographics for the study cohort are outlined in Table 1. There 
was no significant difference in any demographic factor between the control group, 
the treatment group or those 22 who declined study participation. Further, use of 
both opiates and antipruritic medications was similar between the control and the 
treatment groups – no statistically significant difference between groups existed 
when examining the uptake of either drug category.  
 
TAKE IN TABLE 1 HERE. 
 
Mean days prior to the first post-burn cream application were 16 (SD 10; range 3-
50). Mean time in seconds required for cream application between the control and 
the treatment group did not differ significantly (139 seconds control versus 157 
seconds treatment). While the number of cream applications per 24 hour period did 
not significantly differ between the control group and the treatment group, 
participants in the treatment group reported a greater reduction in itch post cream 
application than those in the control group (91% treatment versus 82% control; 
p=0.001). Additionally, itch recurrence following cream application was later in the 
treatment group than in the control group (p≤0.001) (Figure 1). 
 
TAKE IN FIGURE 1 HERE. 
 
No study participant was ordered regular antipruritic medications – antipruritic 
medications for all study participants were charted ‘as required’ (i.e. while 
participants were aware antipruritic medications were charted to relieve itch, they 
only received these medications when they requested them). Use of antipruritic 
medications in the control group was greater than that of the treatment group 
(p=0.023). Sleep disturbance due to itch in this study was limited. While 8.9% of 
study nights resulted in interruption related to itch, most participants were unaffected 
– a few individuals were greatly affected. There was no difference in sleep 
disturbance between the control group and the treatment group. 
 DISCUSSION 
Past studies identified massage as potentially reducing post-burn itch.5,7,14 
Consequently this study recorded the approximate time in seconds each cream 
application required. Taking the mean application time across all cream applications 
in the study, participants in the Medilixir® group required an additional 17 seconds for 
cream application. While this difference may potentially impact upon itch, given an 
approximate cream application time of two and a half minutes, the difference 
between the application of Medilixir® and aqueous cream appears minimal. Similarly, 
participant demographics for both the aqueous group and the Medilixir® group 
closely matched those who declined study participation. ‘PRN’ or ‘as required’ 
antipruritic medications charted for all study participants was again comparable. 
Given these factors it appears reasonable to compare outcomes between 
participants in the aqueous group and participants in the Medilixir® group. 
 
An observation noted by the data collector during the trial was newly healed skin in 
the Medilixir® group appeared supple and moist in comparison to participants in the 
aqueous group whose skin appeared dry. It was assumed that as Medilixir® is oil 
based, the herbal oils and beeswax were moisturizing participant skin with greater 
effect than aqueous cream which is water based. Data was not formally collected 
which examined the condition of the regenerating skin and this observation was 
anecdotal. However, the number of cream applications per 24 hours was recorded 
as was itch recurrence post cream application. Participants in the Medilixir® group 
were found to have fewer cream applications per 24 hour period than those in the 
aqueous group. Despite a noted difference, the small sample size of this pilot study 
requires the frequency of cream application to be considered with caution. Owing to 
the restriction of wound dressings, not all participants could access their newly 
healed skin to apply cream ‘as desired’ at any time outside of their daily wound 
dressing. A trial enrolling more participants would see access to newly regenerated 
skin well distributed across the sample – the same cannot be said with any certainty 
for a group of 52 participants.  
 
A reduction in itch following cream application was more likely to occur for those 
participants managed with Medilixir® (p=0.001). Additionally, itch recurrence post 
cream application occurred later in the Medilixir® group than it did in the aqueous 
cream group. As shown in Figure 1, more than half of all participants in the aqueous 
group who experienced itch recurrence following cream application experienced this 
itch within four hours or less of cream application. In contrast, almost half of all 
participants in the Medilixir® group experiencing itch recurrence following cream 
application, experienced this recurrence between 8 and 24 hours post cream 
application. Of further note when considering the efficacy of Medilixir®, is the use of 
antipruritic medications. While all participants in this study had ‘PRN’ antipruritic 
medications prescribed, antipruritic medication request and use was greatest in the 
aqueous group. Participants in the Medilixir® group were less likely to use antipruritic 
medications than those in the aqueous group (p=0.023).  
 
Four patients were excluded from this study due to reacting to a patch test 
application of Medilixir®. All four participant reactions were similar presenting as mild, 
short term erythema only. It could be assumed the Medilixir® reaction in these four 
participants occurred as a result of an allergy to one or more of the product 
ingredients. No subsequent applications of Medilixir® were applied post reaction, nor 
were further investigations undertaken to determine whether the participant response 
in each instance was linked with cream application. While Medilixir® contained 
beeswax, it was assumed a bee allergy would not necessarily infer an allergy to 
beeswax. Of those participants reacting to Medilixir® none were allergic to bees. No 
participant reacted to the aqueous cream.    
 
Limitations 
The primary limitation of this study was the small sample size. Future studies 
conducted in this area require larger numbers before findings can be accepted with a 
greater degree of confidence. However, it should be recognized that while the 
sample size was not large, all study outcomes favored a single treatment.  
 
CONCLUSION 
Despite the majority of burn patients experiencing the discomfort of post-burn itch 
literature indicates no studies providing a definitive solution to this problem. With 
recent anecdotal evidence provided by burn outpatients to suggest the efficacy of 
Medilixir® in the management of post-burn itch, a randomized controlled trial was 
designed to examine Medilixir® and the standard treatment of aqueous cream 
following burn injury. The findings of this study indicate that in comparison to 
aqueous cream, participants using Medilixir® demonstrate a greater reduction in itch 
following cream application, have a later recurrence of itch symptoms following 
cream application and use antipruritic medications with less frequency. As this pilot 
study suggests Medilixir® to be more effective in the minimization of post-burn itch 
than aqueous cream, a larger study to examine the efficacy of Medilixir® appears 
warranted. 
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FIGURE AND TABLE LEGENDS 
Figure 1: Itch recurrence post moisturizing cream application. 
Table 1: Demographic data of study participants. 
 
 
TABLE 1: Demographic data of study participants. 
Variable  Measure 
Total population, n 52 
Age, mean (SD), y 35 (16) 
Proportion of men, n 44 (84%) 
Comorbidities  
    Any comorbidity, n  16 (30.8%) 
    Hypertension, n 4 (7.7%) 
    Vascular, n 0 (0%) 
    Respiratory, n 1 (1.9%) 
    Neurological, n 2 (3.8%) 
    Connective tissue, n 1 (1.9%) 
    Renal/urinary, n 0 (0%) 
    Cardiac, n 4 (7.7%) 
    Liver, n 1 (1.9%) 
    Pyschological, n 1 (1.9%) 
    Gastrointestinal, n 1 (1.9%) 
    Diabetes, n 2 (3.8%) 
    Other, n 2 (3.8%) 
Burn  
    Total burn surface area, mean (SD), % 7.2 (7.7) 
        Superficial, mean (SD), % 0.7 (2) 
        Partial, mean (SD), % 5.2 (6.5) 
        Full, mean (SD), % 1.3 (3.1) 
    Burn type  
        Flame, n 33 (65.5%) 
        Electrical, n 2 (3.8%) 
        Scald, n 7 (13.5%) 
        Chemical, n 2 (3.8%) 
        Contact, n 1 (1.9%) 
        Oil, n 5 (9.6%) 
        Molten steel, n 2 (3.8%) 
    Location  
        Head, hands and feet, n 16 (30.7%) 
        Other sites, n 36 (69.3%) 
Presence of donor site, n 29 (55.8%) 
 
 
Figure 1: Itch recurrence post moisturizing cream application. 
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